Production of Cisplatin-Incorporating Hyaluronan Nanogels via Chelating Ligand–Metal Coordination

详细信息    查看全文

• 作者：Seiichi Ohta ; Syota Hiramoto ; Yuki Amano ; Mayu Sato ; Yukimitsu Suzuki ; Marie Shinohara ; Shigenobu Emoto ; Hironori Yamaguchi ; Hironori Ishigami ; Yasuyuki Sakai ; Joji Kitayama ; Taichi Ito
• 刊名：Bioconjugate Chemistry
• 出版年：2016
• 出版时间：March 16, 2016
• 年：2016
• 卷：27
• 期：3
• 页码：504-508
• 全文大小：357K
• ISSN：1520-4812

文摘

Hyaluronan (HA) is a promising drug carrier for cancer therapy because of its CD44 targeting ability, good biocompatibility, and biodegradability. In this study, cisplatin (CDDP)-incorporating HA nanogels were fabricated through a chelating ligand–metal coordination cross-linking reaction. We conjugated chelating ligands, iminodiacetic acid or malonic acid, to HA and used them as a precursor polymer. By mixing the ligand-conjugated HA with CDDP, cross-linking occurred via coordination of the ligands with the platinum in CDDP, resulting in the spontaneous formation of CDDP-loaded HA nanogels. The nanogels showed pH-responsive release of CDDP, because the stability of the ligand–platinum complex decreases in an acidic environment. Cell viability assays for MKN45P human gastric cancer cells and Met-5A human mesothelial cells revealed that the HA nanogels selectively inhibited the growth of gastric cancer cells. In vivo experiments using a mouse model of peritoneal dissemination of gastric cancer demonstrated that HA nanogels specifically localized in peritoneal nodules after the intraperitoneal administration. Moreover, penetration assays using multicellular tumor spheroids indicated that HA nanogels had a significantly higher ability to penetrate tumors than conventional, linear HA. These results suggest that chelating-ligand conjugated HA nanogels will be useful for targeted cancer therapy.